

RECEIVED CENTRAL FAX CENTER

MAR 1 4 2007

DLA Piper US LLP 153 Townsend Street, Suite 800 San Francisco, California 94107-1957 www.dlapiper.com

Linda R. Judge linda.judge@dlapiper.com T 415.838.2586

FAX TRANSMISSION COVER SHEET

Date: MARCH 14, 2007

To

Telephone

Fax Number

Attn:

Group Art Unit 1636 United States Patent and

Trademark Office

571/273.8300

From:

Linda R. Judge 415/836.2586

Client-Matter Number:

306229-265

Re:

U.S. Application No.:

10/698,160

Entitled:

CELL-SPECIFIC ADENOVIRUS VECTOR COMPRISING EBV-SPECIFIC

PROMOTER

Filing Date: October 30, 2003

Inventor: Yu, et al.

Art Unit: 1636 Examiner. Guzo, D.

Attorney Docket No.: 3802-191-27

-10- (including this form)

Originals: will not follow

If there is a problem with this transmission, please call DLA Piper Office Services at 415.836.2500, ext. 6104

Message:

Please find the following papers included in this filing:

- Transmittal; and
- 2. Amendment.

Thank you.

CONFIDENTIALITY NOTICE

This communication is ONLY for the person named above. Unless otherwise indicated, it contains information that is confidential, privileged or exempt from disclosure under applicable law. If you are not the person named above, or responsible for delivering it to that person, be aware that disclosure, copying, distribution or use of this communication is strictly PROHIBITED. If you have received it in error, or are uncertain as to its proper handling, please immediately notify us by collect telephone and mail the original to us at the above address. Thank you.

(Form Rev. 8/02/04)

SANF1\356327.1

RECEIVED CENTRAL FAX CENTER

MAR 1 4 2007

TRANSMITTAL FORM		Application No.	10/698,160	
		Filing Date	October 30, 2003	
		First Named Inventor	Yu, et al.	
		Group Art Unit	1636	
(To be used for all correspondence after initial filing)		Examiner Name	Guzo, D.	
Total Number of Pages in this Submission: 9		Attorney Docket No.	3802-191-27 (306229-265)	
ENCLOSURES (check all that apply)				
Fee Transmittal Form Fee attached Amandment/Reply After Final Affildavit/Declaration(s) Extension of Time Request Express Abandonment Request Supplemental Information Disclosure Statement (IDS) Substitute PTO Form 1449	Petition Provisio Combine Attorney 3.71 Sta Change	to Convert to a mal Application and Power of and 37 C.F.R. §3.73(b) and tements and Request for of Attorney Docket Number of Correspondence Address	Appe Appe (App	Allowance Communication to eal Communication to Board of eals and Interferences eal Communication to TC eal Notice, Brief, Reply Brief) rietary Information us Letter tional Enclosure(s): Return Receipt Postcard
Cited References Certified Copy of Priority Document(s) Response to Missing Parts Notice/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	CD, Nur Lands REMARKS: Please addre The Director is connection will specifically income.	duding any extension fees	rge any fees the rewith that have that may be re	at may be required in re been inadvertently omitted,
SIGNATURE OF APPLICANT, ATTORNEY OR AGENT				
Signature Chil Rfulge			Date	3/14/07
Name Linda R. Judge	Linda R. Judge Reg. No. 4		Telephone	415-836-2500
Address 153 Townsend St., Suit	rancisco, CA 94107	Facsimile	415-836-2501	
CERTIFICATE OF FACSIMILE TRANSMISSION I hereby certify that this paper (along with any referred to as being attached or enclosed) is being filed with the United States Patent and Trademark Office by facsimile transmission on the date Indicated below to facsimile No. 571/273-8300. Date: March 14, 2007 Carissa Hemphill Name				

RECEIVED CENTRAL FAX CENTER

MAR 1 4 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Yu, et al. .

Docket No:

3802-191-27

(306229-265)

Serial No.: 10/698,160

Confirmation No.: 9850

Filed:

October 30, 2003

Group Art Unit:

1636

For:

CELL-SPECIFIC ADENOVIRUS

Examiner:

Guzo, D.

VECTOR COMPRSING EBV-SPECIFIC PROMOTER

AMENDMENT

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Responsive to the outstanding Office Action dated December 14, 2006, entry of the following amendments is respectfully requested.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 5 of this paper.